Sera Prognostics Inc.

Sera Prognostics Inc. is a biotechnology company focused on developing innovative maternal and fetal health diagnostics. The primary function of Sera Prognostics is to provide personalized diagnostic tests aimed at improving pregnancy care by predicting risks related to preterm births and other pregnancy complications. By enhancing prenatal health through early detection, Sera Prognostics aims to aid healthcare providers in implementing timely and targeted interventions. The company's flagship test, the PreTRM Test, is a blood test utilized to assess the risk of spontaneous preterm birth. Key sectors impacted by Sera Prognostics include healthcare, biotechnology, and prenatal care services. Sera Prognostics holds a significant role in the medical diagnostics market, contributing towards advancements in maternal health by utilizing proprietary proteomic technology. Through its research and development efforts, the company seeks to advance predictive diagnostics that empower doctors and expectant mothers with actionable health insights, ultimately reducing healthcare costs and improving birth outcomes.